WP_Query Object
(
[query] => Array
(
[post_type] => post
[post_status] => publish
[orderby] => date
[order] => DESC
[ignore_sticky_posts] => 1
[post__not_in] => Array
(
[0] => 379
)
[cat] => 18
[posts_per_page] => 3
)
[query_vars] => Array
(
[post_type] => post
[post_status] => publish
[orderby] => date
[order] => DESC
[ignore_sticky_posts] => 1
[post__not_in] => Array
(
[0] => 379
)
[cat] => 18
[posts_per_page] => 3
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] => articles
[tag] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
=>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => category
[terms] => Array
(
[0] => 18
)
[field] => term_id
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wp_term_relationships
)
[queried_terms] => Array
(
[category] => Array
(
[terms] => Array
(
[0] => 18
)
[field] => term_id
)
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id)
WHERE 1=1 AND wp_posts.ID NOT IN (379) AND (
wp_term_relationships.term_taxonomy_id IN (18)
) AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
GROUP BY wp_posts.ID
ORDER BY wp_posts.post_date DESC
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 1626
[post_author] => 1
[post_date] => 2024-09-17 14:19:51
[post_date_gmt] => 2024-09-17 14:19:51
[post_content] =>
According to the American Heart Association, nearly half of all adults in the U.S. have high blood pressure. Recent studies have suggested that effectively treating obesity with GLP-1 agonists may be key to improving overall heart health. These findings are promising — but additional study is necessary, further highlighting the need for accurate GLP-1 patient data and consistent at-home health monitoring.
Healthcare providers can benefit from high-precision remote monitoring tools like cellular connected scales and blood pressure monitors that offer daily insight into a patient’s weight, BMI, body composition, heart rate, blood pressure and more. With more reliable and consistent patient data, care teams can make more informed decisions about a patient’s GLP-1 medication dosage and overall care plan.
Challenges Surrounding Cardiovascular Health
Right now, only one in four adults in the U.S. with hypertension (defined as blood pressure consistently above 130/80 mm Hg) has the condition well managed. Care teams have long struggled to find effective means to help their patients achieve better blood pressure control. It’s a challenge due to patients’ lack of adherence to long-term medication use, as well as difficulties in identifying poor blood pressure control and modifying therapy accordingly.
Healthcare providers already prescribe a range of medications, including diuretics, beta-blockers, and ACE inhibitors, to help patients get their blood pressure into a safe range. Safely administering blood pressure medications – with or without the addition of GLP-1s – is a balancing act. Even in the best of circumstances, patients often need dose adjustments.
Though titration of hypertension medication has been based on in-office blood pressure measurements, this has proven to be inadequate. Readings in an office setting may be artificially elevated due to white coat syndrome. In fact, the fallibility of these measurements led the International Society of Hypertension to recommend that hypertension diagnosis be confirmed by out–of-office blood pressure monitoring.
Even if in-office readings were 100% accurate, it’s simply not practical for patients to come to the office for daily monitoring to see how they’re adjusting to blood pressure medication.
The Value of Remote Biomarker Monitoring
While emerging therapies like GLP-1s hold the promise of reducing blood pressure, they’re not yet approved specifically for that purpose. Plus, studies have found that some GLP-1 medications may increase a patient’s heart rate.The novelty and uncertainty surrounding the effects of GLP-1s highlight the value of long-term at-home monitoring of weight, blood pressure, and other daily biomarkers under real-world conditions. This ensures that care teams can promptly access necessary data for timely intervention.
In addition, health programs can analyze the data they collect from in-home devices and produce robust research demonstrating the value of their program and GLP-1 treatment approach. Continuous remote monitoring not only equips healthcare professionals with the insights needed for precise decision-making — it also lays the groundwork for pioneering developments in personalized medicine and proactive health management strategies.
Motivating Patients on Their Health Journeys
Providers agree that non pharmacological lifestyle interventions are also crucial to improving a patient’s cardiovascular health. Studies have found that tailored and personalized health messages can be particularly effective in motivating patients to make healthy lifestyle choices. But this can be time-consuming for providers.
With more advanced monitoring devices that go beyond biomarker tracking, patients can receive automated messages and alerts from their care teams based on their daily measurements.These notifications appear on the screen of their medical device and may celebrate a milestone or serve as a medication or appointment reminder.
Fortunately, nearly a quarter of Americans are already using monitoring technology to help with motivation and accountability for health goals. Incorporating patient monitoring technology takes this one step further.
Finding an Accurate, Insightful Solution
Kristin Baier, MD, VP of Clinical Development at Calibrate, a leading clinician-guided and value-based obesity treatment program, expressed the need to ensure safety and appropriate weight loss rates for patients on GLP-1 medication who are remotely monitored by healthcare providers. She noted the challenge of not being able to physically assess health metrics like weight and blood pressure without patients visiting a clinic and wanted to ensure the seamless transfer of data into the company’s electronic medical records for long-term tracking. Remotely monitoring patients allows care program providers, like Calibrate, to deliver effective, high-quality medical care to their members over time so that they can successfully analyze trends and tailor recommendations to ensure sustainable results.
High-precision remote monitoring responds to this concern and rises to the challenge, as it provides:
- Accurate and consistent collection of blood pressure, weight, body composition, and other key metrics from the comfort of the patient’s home
- Automatic transmission of this data to the patient’s care team
- Swift provider insight into patient well-being so patterns can be identified and medications or care plans can be adjusted
- Better patient/provider communication and shared-decision making
Moving Forward
In this new era of GLP-1 medications, official scientific guidelines from organizations such as the ADA, EASD, AACE, ACC, and AHA recommend regular monitoring of blood pressure in patients on GLP-1 therapies as part of comprehensive cardiovascular risk management. Remote monitoring will also enable expanded research into the impact of GLP-1s on heart health, offering promising avenues for innovative chronic condition management strategies.
Disclaimer: The information provided in this article is informational and for content marketing purposes only. It should not be construed as medical advice. The content herein is not intended to replace professional medical consultation, diagnosis, or treatment. We expressly recommend that individuals seek advice from a qualified healthcare professional before considering the use of GLP-1 medications for the treatment of obesity or any other condition.
[post_title] => Heart Health in the GLP-1 Era: The Role of Remote Patient Monitoring
[post_excerpt] => Healthcare providers can benefit from high-precision remote monitoring tools like cellular connected scales and blood pressure monitors that offer daily insight into a patient’s weight, BMI, body composition, heart rate, blood pressure and more.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => heart-health-in-the-glp-1-era-the-role-of-remote-patient-monitoring
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-25 20:59:01
[post_modified_gmt] => 2024-09-25 20:59:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://withingshealthsolutions.com/?p=1626
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 1596
[post_author] => 8
[post_date] => 2024-09-03 19:28:05
[post_date_gmt] => 2024-09-03 19:28:05
[post_content] =>
In April 2024, the Journal of Diabetes and Its Complications published “Contemporary prevalence of diabetic neuropathies in individuals with Type 1 and Type 2 diabetes in a Danish tertiary outpatient clinic”, a large scale study from researchers at the Steno Diabetes Center in Copenhagen, Denmark. Researchers assessed 822 individuals with Type 1 and 899 individuals with Type 2 diabetes for both distal symmetric polyneuropathy (DPN) and diabetic autonomic neuropathy (DAN) using a variety of modalities in order to make population-based prevalence estimates.
Where they exist, past estimates of various neuropathies have shown wide ranges of prevalence. In the Steno study, DPN was assessed using vibration perception threshold (VPT), sural nerve function, touch, pain, and thermal sensation. DAN was assessed using cardiovascular reflex tests, electrochemical skin conductance, and gastroparesis cardinal symptom index.
Batteries of DPN methods were applied for 4 groups by adding modalities to each group from large fiber neuropathy with VPT above 25 V and/or abnormal touch sensations (reflecting how DPN is currently assessed in a diabetes clinic setting) to VPT using age-height-sex specific cutoffs, to sural nerve conduction, and finally to small fiber neuropathy as measured by Sudoscan in the feet, abnormal pain and/or abnormal thermal sensation. For DAN, Sudoscan was used to evaluate sudomotor function as measured by electrochemical skin conductance in the feet and hands along with cardiovascular autonomic neuropathy measured by a Vagus device, and orthostatic hypotension based on supine and standing blood pressure.
Prevalence of DPN varied depending on the modalities applied for Type 1 and Type 2 diabetes. Including small fiber neuropathy as measured by Sudoscan increased the prevalence of definite DPN diagnosed by Toronto consensus criteria, from 46 to 54% for Type 1 and from 54 to 68% for Type 2. In contrast, monofilament had the lowest overlap with other diagnostic modalities. Touch sensation showed the lowest prevalence of DPN, perhaps because it can only measure more severe neuropathy. The prevalence of DPN measured by Sudoscan in the feet was twice as high for Type 1 diabetes and 10% higher for Type 2 as the commonly used VPT above 25 V.
Assessing both large and small fiber neuropathy using a variety of modalities was found to be the best way to increase the prevalence of DPN and DAN diagnoses. Measuring small fiber neuropathy was recommended by the researchers for early detection. Small fiber neuropathy, they noted, is not detected using the tools commonly used in diabetes care today.
Interested in partnering with us?
Contact Us
[post_title] => Using a Variety of Modalities to Measure Both Small and Large Fiber Neuropathy Provides More Accurate Estimates of the Prevalence of Diabetic Neuropathies
[post_excerpt] => In April 2024, the Journal of Diabetes and Its Complications published “Contemporary prevalence of diabetic neuropathies in individuals with Type 1 and Type 2 diabetes in a Danish tertiary outpatient clinic”, a large scale study from researchers at the Steno Diabetes Center in Copenhagen, Denmark. Researchers assessed 822 individuals with Type 1 and 899 individuals with Type 2 diabetes for both distal symmetric polyneuropathy (DPN) and diabetic autonomic neuropathy (DAN) using a variety of modalities in order to make population-based prevalence estimates.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => using-a-variety-of-modalities-to-measure-both-small-and-large-fiber-neuropathy-provides-more-accurate-estimates-of-the-prevalence-of-diabetic-neuropathies
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 13:43:51
[post_modified_gmt] => 2024-09-04 13:43:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://withingshealthsolutions.com/?p=1596
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 1594
[post_author] => 8
[post_date] => 2024-09-03 19:24:05
[post_date_gmt] => 2024-09-03 19:24:05
[post_content] =>
A number of major new studies and advancements related to screening for diabetic peripheral neuropathy (DPN) were presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando.
The headliner was a longitudinal study - “Combined DPNCheck and SUDOSCAN as a Screening Tool for DPN—The Sheffield Prospective Study” - presented by Dr. Mohummad Shaan Goonoo of Sheffield Teaching Hospitals and NHS Foundation Trust. Dr. Goonoo presented data that evaluated the ability of point-of-care-devices (POCDs) to accurately diagnose DPN. The POCDs used were Withings SUDOSCAN, incorporating our Electrochemical Skin Conductance (ESC) technology, and DPNCheck, a handheld device which measures sural nerve conduction-velocity/amplitude.
In the study, 229 participants with diabetes who attended a one-stop microvascular screening service were re-called for follow-up evaluation at 7 years. Baseline assessments were repeated including: Toronto Clinical Neuropathy Score, 10g monofilament, SUDOSCAN and DPNCheck, and nerve conduction studies.
The study demonstrated significantly increased risk of incident clinical DPN in patients with abnormal baseline POCDs (microalbuminuria equivalent). The findings supported the use of POCDs as a screening tool for early DPN diagnosis, when cardio-metabolic control may halt the progressive neuropathic process.
Improving DFU Risk Stratification
A separate study was presented in a poster session entitled “Improving Diabetic Foot Ulcer (DFU) Management with Electrochemical Skin Conductance (ESC)”. The study, which also used Withings ESC technology, assessed the association between ESC measures and DFU risk stratification scores in 2157 diabetic patients from four French hospitals.
Interested in partnering with us?
Contact Us
[post_title] => Diabetic Neuropathy Research and Withings Technologies Highlighted at The American Diabetes Association’s 84th Scientific Sessions
[post_excerpt] => When the world’s leading clinicians and researchers gather later this month in Orlando, Florida at ADA’s 84th Scientific Sessions, diabetic peripheral neuropathy and diabetic foot ulcer prevention will be spotlighted.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => diabetic-neuropathy-research-and-withings-technologies-highlighted-at-the-american-diabetes-associations-84th-scientific-sessions
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-03 19:24:06
[post_modified_gmt] => 2024-09-03 19:24:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://withingshealthsolutions.com/?p=1594
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 3
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 1626
[post_author] => 1
[post_date] => 2024-09-17 14:19:51
[post_date_gmt] => 2024-09-17 14:19:51
[post_content] =>
According to the American Heart Association, nearly half of all adults in the U.S. have high blood pressure. Recent studies have suggested that effectively treating obesity with GLP-1 agonists may be key to improving overall heart health. These findings are promising — but additional study is necessary, further highlighting the need for accurate GLP-1 patient data and consistent at-home health monitoring.
Healthcare providers can benefit from high-precision remote monitoring tools like cellular connected scales and blood pressure monitors that offer daily insight into a patient’s weight, BMI, body composition, heart rate, blood pressure and more. With more reliable and consistent patient data, care teams can make more informed decisions about a patient’s GLP-1 medication dosage and overall care plan.
Challenges Surrounding Cardiovascular Health
Right now, only one in four adults in the U.S. with hypertension (defined as blood pressure consistently above 130/80 mm Hg) has the condition well managed. Care teams have long struggled to find effective means to help their patients achieve better blood pressure control. It’s a challenge due to patients’ lack of adherence to long-term medication use, as well as difficulties in identifying poor blood pressure control and modifying therapy accordingly.
Healthcare providers already prescribe a range of medications, including diuretics, beta-blockers, and ACE inhibitors, to help patients get their blood pressure into a safe range. Safely administering blood pressure medications – with or without the addition of GLP-1s – is a balancing act. Even in the best of circumstances, patients often need dose adjustments.
Though titration of hypertension medication has been based on in-office blood pressure measurements, this has proven to be inadequate. Readings in an office setting may be artificially elevated due to white coat syndrome. In fact, the fallibility of these measurements led the International Society of Hypertension to recommend that hypertension diagnosis be confirmed by out–of-office blood pressure monitoring.
Even if in-office readings were 100% accurate, it’s simply not practical for patients to come to the office for daily monitoring to see how they’re adjusting to blood pressure medication.
The Value of Remote Biomarker Monitoring
While emerging therapies like GLP-1s hold the promise of reducing blood pressure, they’re not yet approved specifically for that purpose. Plus, studies have found that some GLP-1 medications may increase a patient’s heart rate.The novelty and uncertainty surrounding the effects of GLP-1s highlight the value of long-term at-home monitoring of weight, blood pressure, and other daily biomarkers under real-world conditions. This ensures that care teams can promptly access necessary data for timely intervention.
In addition, health programs can analyze the data they collect from in-home devices and produce robust research demonstrating the value of their program and GLP-1 treatment approach. Continuous remote monitoring not only equips healthcare professionals with the insights needed for precise decision-making — it also lays the groundwork for pioneering developments in personalized medicine and proactive health management strategies.
Motivating Patients on Their Health Journeys
Providers agree that non pharmacological lifestyle interventions are also crucial to improving a patient’s cardiovascular health. Studies have found that tailored and personalized health messages can be particularly effective in motivating patients to make healthy lifestyle choices. But this can be time-consuming for providers.
With more advanced monitoring devices that go beyond biomarker tracking, patients can receive automated messages and alerts from their care teams based on their daily measurements.These notifications appear on the screen of their medical device and may celebrate a milestone or serve as a medication or appointment reminder.
Fortunately, nearly a quarter of Americans are already using monitoring technology to help with motivation and accountability for health goals. Incorporating patient monitoring technology takes this one step further.
Finding an Accurate, Insightful Solution
Kristin Baier, MD, VP of Clinical Development at Calibrate, a leading clinician-guided and value-based obesity treatment program, expressed the need to ensure safety and appropriate weight loss rates for patients on GLP-1 medication who are remotely monitored by healthcare providers. She noted the challenge of not being able to physically assess health metrics like weight and blood pressure without patients visiting a clinic and wanted to ensure the seamless transfer of data into the company’s electronic medical records for long-term tracking. Remotely monitoring patients allows care program providers, like Calibrate, to deliver effective, high-quality medical care to their members over time so that they can successfully analyze trends and tailor recommendations to ensure sustainable results.
High-precision remote monitoring responds to this concern and rises to the challenge, as it provides:
- Accurate and consistent collection of blood pressure, weight, body composition, and other key metrics from the comfort of the patient’s home
- Automatic transmission of this data to the patient’s care team
- Swift provider insight into patient well-being so patterns can be identified and medications or care plans can be adjusted
- Better patient/provider communication and shared-decision making
Moving Forward
In this new era of GLP-1 medications, official scientific guidelines from organizations such as the ADA, EASD, AACE, ACC, and AHA recommend regular monitoring of blood pressure in patients on GLP-1 therapies as part of comprehensive cardiovascular risk management. Remote monitoring will also enable expanded research into the impact of GLP-1s on heart health, offering promising avenues for innovative chronic condition management strategies.
Disclaimer: The information provided in this article is informational and for content marketing purposes only. It should not be construed as medical advice. The content herein is not intended to replace professional medical consultation, diagnosis, or treatment. We expressly recommend that individuals seek advice from a qualified healthcare professional before considering the use of GLP-1 medications for the treatment of obesity or any other condition.
[post_title] => Heart Health in the GLP-1 Era: The Role of Remote Patient Monitoring
[post_excerpt] => Healthcare providers can benefit from high-precision remote monitoring tools like cellular connected scales and blood pressure monitors that offer daily insight into a patient’s weight, BMI, body composition, heart rate, blood pressure and more.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => heart-health-in-the-glp-1-era-the-role-of-remote-patient-monitoring
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-25 20:59:01
[post_modified_gmt] => 2024-09-25 20:59:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://withingshealthsolutions.com/?p=1626
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 29
[max_num_pages] => 10
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] => 1
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => f1c78d32b4a5ea84695dc67a9274d272
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
